• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zai Lab Limited - American Depositary Shares (NQ:ZLAB)

29.40 -1.83 (-5.86%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Zai Lab Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 Next >
Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
October 13, 2025
From Zai Lab Limited
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab Limited - ZLAB
September 06, 2025
From Pomerantz LLP
Via GlobeNewswire
Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong
September 01, 2025
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Participation in Investor Conferences in September 2025
August 28, 2025
From Zai Lab Limited
Via Business Wire
Zai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic Cancer
August 19, 2025
From Zai Lab Limited
Via Business Wire
Zai Lab Establishes Oncology Scientific Advisory Board
August 13, 2025
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates
August 07, 2025
From Zai Lab Limited
Via Business Wire
Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025
July 10, 2025
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer
June 30, 2025
From Zai Lab Limited
Via Business Wire
Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025
June 13, 2025
From Zai Lab Limited
Via Business Wire
Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting
June 02, 2025
From Zai Lab Limited
Via Business Wire
Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
May 31, 2025
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Participation in Investor Conferences in June 2025
May 30, 2025
From Zai Lab Limited
Via Business Wire
Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer
May 19, 2025
From Zai Lab Limited
Via Business Wire
Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates
May 08, 2025
From Zai Lab Limited
Via Business Wire
Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025
April 25, 2025
From Zai Lab Limited
Via Business Wire
Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting
April 23, 2025
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors
April 21, 2025
From Zai Lab Limited
Via Business Wire
Zai Lab to Announce First Quarter 2025 Financial Results and Recent Corporate Updates on May 8, 2025
April 14, 2025
From Zai Lab Limited
Via Business Wire
Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting
March 26, 2025
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer
March 12, 2025
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Participation in Investor Conferences in March 2025
March 03, 2025
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates
February 27, 2025
From Zai Lab Limited
Via Business Wire
Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025
January 28, 2025
From Zai Lab Limited
Via Business Wire
Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)
January 22, 2025
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia
January 17, 2025
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer
January 15, 2025
From Zai Lab Limited
Via Business Wire
Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore
January 10, 2025
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore
January 10, 2025
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate
January 09, 2025
From Zai Lab Limited
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Recent Quotes
View More
Symbol Price Change (%)
GOOG  246.19
+1.55 (0.63%)
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap